Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|LN-145||LN145||LN145 comprises autologous tumor infiltrating lymphocytes that are isolated and expanded with IL-2, followed by infusion, potentially resulting in tumor cell death (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03083873||Phase II||LN-145||Study of LN-145 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck||Recruiting|
|NCT03645928||Phase II||LN-144 + Pembrolizumab LN-145 LN-145 + Pembrolizumab||Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors||Recruiting|
|NCT03108495||Phase II||LN-145||Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma||Recruiting|
|NCT03419559||Phase II||LN-145 Durvalumab + LN-145||Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combo With Durvalumab in Non-Small Cell Lung Cancer||Withdrawn|
|NCT04111510||Phase II||LN-145||Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer||Recruiting|